Withdrawal phenomenon with the antiandrogen casodex - Editorial comment Journal Article


Authors: Scher, H. I.; Kelly, W. K.
Article Title: Withdrawal phenomenon with the antiandrogen casodex - Editorial comment
Abstract: Total androgen blockade with castration and antiandrogens has become the primary therapy in metastatic prostate carcinoma. Several reports have been published on the flutamide withdrawal syndrome with a favorable response in patients with progression of disease after lengthy remission while taking combined hormone therapy. The experience with withdrawal of the experimental nonsteroidal antiandrogen casodex * in 3 patients is reported. All patients received casodex monotherapy initially, then luteinizing hormone-releasing hormone analogues were added on progression of disease (bone scan and prostate specific antigen (PSA)) and eventually casodex was withdrawn on further progression of disease (PSA and bone scan). © 1995 American Urological Association, Inc.
Keywords: aged; aged, 80 and over; clinical feature; case report; drug withdrawal; antineoplastic agents; prostate specific antigen; withdrawal syndrome; gonadorelin; cancer hormone therapy; prostate-specific antigen; prostatic neoplasms; bicalutamide; flutamide; anilides; bone scintiscanning; prostate carcinoma; human; male; priority journal; article; substance withdrawal syndrome
Journal Title: Journal of Urology
Volume: 153
Issue: 3 Suppl.
ISSN: 0022-5347
Publisher: Elsevier Science, Inc.  
Date Published: 1995-03-01
Start Page: 1072
End Page: 1073
Language: English
PROVIDER: scopus
DOI: 10.1016/S0022-5347(01)69870-7
DOI/URL:
Notes: Article -- See DOI 10.1016/s0022-5347(01)67644-4 and PMID 7531785 for article under discussion and text of the comment -- Export Date: 28 August 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. William K Kelly
    115 Kelly
  2. Howard Scher
    1130 Scher